Retatrutide (LY3437943), being a GLP-1, GIP, and glucagon receptors agonist, has been the first one to enter clinical trials for the treatment of T2DM and obesity [163]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.